CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Back to ALPMY

Enfortumab vedotin

Phase 3
Astellas Pharma (ALPMY)

Phase 3

Development Phase

2

Upcoming Catalysts

0

Historical Events

0

Regulatory Approvals

Upcoming Catalysts
What are catalysts?
Jun '27
ALPMYPhase 2

Enfortumab Vedotin Phase 2 Est. Readout

Enfortumab vedotin
Jun 2027~
CT.gov
00%
Dec '26
ALPMYPhase 2

Enfortumab Vedotin Phase 2 Est. Readout

Enfortumab vedotin
Dec 2026~
CT.gov
00%
Competitive Landscape

0 competitors in Metastatic Urothelial Cancer

View Full Landscape
Drug Information

Target Indication

Metastatic Urothelial Cancer

Clinical Trial

NCT04995419

Last updated: 7/18/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.